Lung cancer is the leading cause of cancer deaths worldwide, mainly because it gets detected late. The discovery by the ...

They also found EGFR in the active conformation and wondered why this conformation seemed to be favored when crystallized (Zhang et al. 2006). They found that by mutating a residue in the kinase ...

The ERBB receptors are a group of receptor tyrosine kinases (RTKs) involved in key cellular functions including cell growth and survival. What are the activation mechanisms particular to ERBBs?

EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs), given their low molecular weight, may be able to reach a higher concentration in brain tissues. Various reports and small studies ...

For example, EGFR 19 deletions and EGFR L858R point mutations respond well to tyrosine kinase inhibitors (TKIs), which are also called EGFR inhibitors. Drugs that target the EGFR protein and block ...

More information: Shen Yon Toh et al, Therapeutic application of extracellular vesicular EGFR isoform D as a co-drug to ...

During a Community Case Forum event in partnership with the Texas Society of Clinical Oncology, Natalie Vokes, MD, discussed trials of targeted agents for EGFR-mutant lung cancer.

multicenter RAMOSE trial indicate that the addition of ramucirumab to osimertinib significantly prolongs PFS in TKI [tyrosine kinase inhibitor]-naive patients with NSCLC harboring classical EGFR ...

Lung cancer remains one of the leading causes of cancer-related mortality, with lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) representing the most prevalent subtypes of non-small ...

locally advanced or metastatic non-squamous non-small cell lung cancer [NSCLC] who have progressed after treatment with a 3rd generation EGFR Tyrosine Kinase Inhibitor [TKI]. Such data from this ...